The Norwegian Cancer Symposium 2020


-       from a prostate cancer perspective

September 17th-18th, 2020
Oslo, Norway

We are excited to have brought together top-ranking researchers, clinicians, industry and policymakers for this 2-day symposium to strengthen the collaboration between stakeholders in biomarker-driven cancer care, with the aim to overcome bottlenecks and hurdles for implementing true precision medicine in the clinic.

NYU and The Manhattan Veterans Hospital (US)
Univ.Hospital St. Etienne and Univ. of Jean Monnet (FR)
Radboud Institute for Molecular Life Sciences and Radboud Univ. MC (NL)
Dana Farber Cancer Institute, MA (US)
The ICR and The Royal Marsden NHS Foundation Trust (UK)
Univ. of Central Florida's College of Medicine and ConfluenceStat LLC (US)
Karolinska Institutet and Capio S:t Göran Hospital (SE)
Univ. of Oxford, Queen’s Univ. of Belfast and Univ. of Cambridge (UK)
Manchester Cancer Research Centre, CRUK, and Univ. of Manchester (UK)
Erasmus MC (NL)
SciLife Laboratory, Karolinska Institutet (SE)
Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)
University of Bern (CH)
Erasmus MC (NL)
Exosome Diagnostics, Inc., Cambridge (US)
Oslo Univ. Hospital (NO)
Oslo Univ. Hospital and
Univ. of Oslo (NO)
Oslo Univ. Hospital and Univ. of Oslo (NO)
Show More

The speakers will cover topics on how molecular tests can enable sustainable and cost-effective precision in the clinic, how to exploit the complex interplay between tumour and microenvironment, and tools to discover and validate clinically relevant biomarkers.



For questions and comments email

 Please Note:

Limited spaces available,

early registration recommended